CINECA IRIS Institutional Research Information System

DE NICOLO', Amedeo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.278
AS - Asia 5.320
EU - Europa 4.829
SA - Sud America 713
AF - Africa 147
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 8
Totale 21.327
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.077
SG - Singapore 2.291
CN - Cina 1.403
IT - Italia 1.099
DK - Danimarca 580
VN - Vietnam 570
BR - Brasile 518
IE - Irlanda 481
FR - Francia 469
SE - Svezia 435
DE - Germania 358
AT - Austria 282
FI - Finlandia 268
GB - Regno Unito 216
IN - India 214
UA - Ucraina 165
KR - Corea 162
HK - Hong Kong 153
CA - Canada 97
NL - Olanda 92
JP - Giappone 91
ID - Indonesia 82
BD - Bangladesh 69
AR - Argentina 67
MX - Messico 64
PL - Polonia 59
IQ - Iraq 57
ES - Italia 56
CZ - Repubblica Ceca 40
RU - Federazione Russa 39
CH - Svizzera 37
ZA - Sudafrica 37
BE - Belgio 36
AU - Australia 30
CL - Cile 29
TR - Turchia 27
EG - Egitto 25
TH - Thailandia 24
VE - Venezuela 23
EC - Ecuador 22
PK - Pakistan 22
CO - Colombia 21
GR - Grecia 21
HR - Croazia 19
RO - Romania 19
UZ - Uzbekistan 18
MA - Marocco 16
PY - Paraguay 13
TW - Taiwan 13
KE - Kenya 12
AE - Emirati Arabi Uniti 10
NG - Nigeria 10
JM - Giamaica 9
JO - Giordania 9
PE - Perù 9
PH - Filippine 9
SN - Senegal 9
DZ - Algeria 8
EU - Europa 8
IL - Israele 8
LT - Lituania 8
MY - Malesia 8
PS - Palestinian Territory 8
PT - Portogallo 8
SA - Arabia Saudita 8
TN - Tunisia 8
AZ - Azerbaigian 7
RS - Serbia 7
UY - Uruguay 7
BY - Bielorussia 6
KG - Kirghizistan 6
QA - Qatar 6
CR - Costa Rica 5
GE - Georgia 5
KZ - Kazakistan 5
LV - Lettonia 5
NO - Norvegia 5
TT - Trinidad e Tobago 5
ET - Etiopia 4
KW - Kuwait 4
LB - Libano 4
NP - Nepal 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HN - Honduras 3
IR - Iran 3
LK - Sri Lanka 3
MN - Mongolia 3
BF - Burkina Faso 2
BG - Bulgaria 2
BH - Bahrain 2
BS - Bahamas 2
BW - Botswana 2
EE - Estonia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
ME - Montenegro 2
ML - Mali 2
Totale 21.283
Salva come PNG Salva come JPEG
Città #
Singapore 1.317
Ann Arbor 1.314
Chandler 984
Ashburn 734
Beijing 654
Santa Clara 571
San Jose 530
Dublin 479
Fairfield 341
Torino 312
Houston 296
Woodbridge 252
Nyköping 221
Vienna 218
Dearborn 195
Villeurbanne 190
Wilmington 184
Ho Chi Minh City 155
Los Angeles 148
Columbus 146
Turin 145
Medford 141
Princeton 133
The Dalles 130
Lauterbourg 129
Seattle 124
Hong Kong 119
Hanoi 118
Cambridge 117
Dallas 112
New York 107
Hefei 106
Seoul 106
Fremont 102
Redwood City 96
Jacksonville 95
Munich 89
Buffalo 84
Helsinki 71
Boardman 62
Milan 62
Jakarta 60
Tokyo 60
São Paulo 55
Orem 51
Boston 50
Nuremberg 49
Dong Ket 43
Redondo Beach 42
Guangzhou 41
Shanghai 41
Burlington 40
Warsaw 40
Bengaluru 39
Council Bluffs 39
Turku 39
Washington 39
Toronto 38
Pisa 37
Verona 37
Frankfurt am Main 35
Nanjing 35
Hangzhou 34
London 32
Brussels 29
Mexico City 27
Rome 27
Brno 26
Da Nang 26
Mumbai 26
San Diego 25
Baghdad 23
Lappeenranta 23
Chennai 22
Chicago 21
Phoenix 21
Rio de Janeiro 20
Amsterdam 19
Hebei 19
Manchester 19
Silver Spring 19
Atlanta 18
Chengdu 18
Norwalk 18
Belo Horizonte 17
Düsseldorf 17
Haiphong 17
Memphis 17
Stockholm 17
Zagreb 16
Montreal 15
San Francisco 15
Hyderabad 14
Zurich 14
Brooklyn 13
Jinan 13
Barcelona 12
Biên Hòa 12
Des Moines 12
Johannesburg 12
Totale 13.144
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 485
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 468
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 309
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 292
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 285
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 285
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 283
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 280
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 274
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 255
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 249
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study 247
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 239
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 233
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 230
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 218
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 216
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 216
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 215
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir 211
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 205
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension 202
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 201
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 200
An UPLC MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in Peripheral Blood Mononuclear Cells 198
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 196
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 196
Pharmacokinetic and pharmacogenetic analysis of tacrolimus in pediatric liver transplant patients in the early post-liver transplantation period 194
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 193
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 193
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 192
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 191
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 191
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 187
Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis 186
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 184
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 183
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 183
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 181
Quantification of tacrolimus in PBMCs samples in pediatric liver transplant patients and correlation with tacrolimus whole blood concentration 179
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 176
Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment? 175
A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring 170
Pharmacogenetics of ribavirin-induced anemia in HCV patients 169
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 169
Cannabinoids concentration variability in cannabis olive oil galenic preparations 169
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 168
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 164
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 159
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients 159
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 156
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants 153
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 149
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 146
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients 145
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 143
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 141
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 140
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 140
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening 140
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples 139
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 139
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma 139
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 137
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 137
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 136
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 134
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 134
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 133
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration 133
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 131
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 131
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 130
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 128
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 128
A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues 127
Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients 125
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 125
Analytical validation of a novel UHPLC-MS/MS method for 19 antibiotics quantification in plasma: Implementation in a LC-MS/MS Kit 124
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 124
A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients 122
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting 121
UHPLC-MS/MS Method with On-line SPE to Quantify Tacrolimus and Everolimus in Peripheral Blood Mononuclear Cells: Application of “IS-normalized” Matrix Effect 121
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 121
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 121
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 120
First UHPLC MS/MS method coupled with automated on-line SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients 119
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells 117
UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples 117
Pharmacogenetic of voriconazole antifungal agent in pediatric patients 116
A new UHPLC-MS/MS method for cannabinoids determination in human plasma: A clinical tool for therapeutic drug monitoring 115
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 115
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 114
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 113
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 113
Seasonal variation of antiretroviral drug exposure during the year: The experience of 10 years of therapeutic drug monitoring 113
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia 112
Therapeutic drug monitoring guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence 111
Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy 109
UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists' drugs in human plasma 109
Totale 17.409
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.807
article - articoli 0
book - libri 0
conference - conferenze 9.479
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.286
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021284 0 0 0 0 0 0 0 0 0 0 0 284
2021/20222.447 176 193 196 196 156 213 181 152 114 129 388 353
2022/20232.773 249 234 71 258 253 659 164 230 315 61 182 97
2023/20241.120 154 194 78 54 64 152 28 51 13 59 103 170
2024/20253.237 52 154 133 285 798 246 82 156 359 196 286 490
2025/20266.481 785 350 413 791 684 358 1.056 341 564 523 475 141
Totale 22.131